Clinical Trial Update: Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis [Phase 1]

View source ↗

Summary

Phase 1 safety and tolerability study of MEDI-551, a B-cell depleting agent, for relapsing forms of multiple sclerosis completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• MEDI-551 (inebilizumab)

Snippet

Sponsor: MedImmune LLC | Conditions: Multiple Sclerosis, Relapsing Forms | Phase 1 | Status: COMPLETED | Results posted: 2018-10-29